Author:
Penack Olaf,Dreger Peter,Ajib Salem,Ayuk Francis,Baermann Ben-Niklas,Bug Gesine,Kriege Oliver,Jentzsch Madlen,Kobbe Guido,Koenecke Christian,Lutz Mathias,Martin Sonja,Schlegel Paul-Gerhard,Schroers Roland,von Tresckow Bastian,Vucinic Vladan,Subklewe Marion,Bethge Wolfgang,Wolff Daniel
Abstract
<b><i>Introduction:</i></b> Chimeric antigen receptor positive T cell (CAR-T cell) treatment became standard therapy for relapsed or refractory hematologic malignancies, such as non-Hodgkin’s lymphoma and multiple myeloma. Owing to the rapidly progressing field of CAR-T cell therapy and the lack of generally accepted treatment guidelines, we hypothesized significant differences between centers in the prevention, diagnosis, and management of short- and long-term complications. <b><i>Methods:</i></b> To capture the current CAR-T cell management among German centers to determine the medical need and specific areas for future clinical research, the DAG-HSZT (Deutsche Arbeitsgemeinschaft für Hämatopoetische Stammzelltransplantation und Zelluläre Therapie; German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy) performed a survey among 26 German CAR-T cell centers. <b><i>Results:</i></b> We received answers from 17 centers (65%). The survey documents the relevance of evidence in the CAR-T cell field with a homogeneity of practice in areas with existing clinical evidence. In contrast, in areas with no – or low quality – clinical evidence, we identified significant variety in management in between the centers: management of cytokine release syndrome, immune effector cell-related neurotoxicity syndrome, IgG substitution, autologous stem cell backups, anti-infective prophylaxis, and vaccinations. <b><i>Conclusion:</i></b> The results indicate the urgent need for better harmonization of supportive care in CAR-T cell therapies including clinical research to improve clinical outcome.
Subject
Cancer Research,Oncology,Hematology